Genetic alterations and polymorphisms in gastric cancer

Journal of the Formosan Medical Association

Volumn 102, Issue 7, 2003, Pages 447-458

  Wu, Ming Shiang ^a   Chen, Chien Jen ^b   Lin, Jaw Town ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Genetic predisposition to disease; Genetic research; Polymorphism (genetics); Review neoplasms

Indexed keywords

APC PROTEIN; BETA CATENIN; CARCINOGEN; PROTEIN MLH1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UVOMORULIN;

CANCER CLASSIFICATION; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CANCER SUSCEPTIBILITY; CELL GROWTH; DISEASE ASSOCIATION; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENE TARGETING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; GERM LINE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INHERITANCE; MEDICAL TECHNOLOGY; MUTATOR GENE; ONCOGENE; PATHOGENESIS; PENETRANCE; PHENOTYPE; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; SUPPRESSOR GENE; TREATMENT PLANNING; TUMOR CELL; TUMOR SUPPRESSOR GENE;

DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 0348161058     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Wu MS, Lin JT, Lee WJ, et al: Gastric cancer in Taiwan. J Formos Med Assoc 1993;93:S77-S89.
2. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-S6.
3. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995; 333:32-41.
4. Tahara E, Semba S, Tahara H: Molecular biological observations in gastric cancer. Semin Oncol 1996;23:307-15.
5. Wu MS, Yang KC, Shun CT, et al.: Distinct clinicopathologic characteristics of diffuse and intestinal type gastric cancer in Taiwan. J Clin Gastroenterol 1997;24:646-9.
6. Wu MS, Chen SY, Shun CT, et al: Increased prevalence of Helicobacter pylori infection among patients affected with intestinal-type gastric cancer at non-cardiac locations. J Gastroenterol Hepatol 1997;12:425-8.
7. Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science 2002;298:2345-9.
8. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100:57-70.
9. Marsh DJ, Zori RT: Genetic insights into familial cancers-update and recent discoveries. Cancer Lett 2002;181:125-64.
10. Redston M: Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol 2001;14:236-45.
11. Houlston RS, Tomlinson IP: Detecting low penetrance genes in cancer: the way ahead. J Med Genet 2000;37:161-7.
12. Laken SJ, Petersen GM, Gruber SB, et al.: Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
13. El-Omar EM, Carrington M, Chow-WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
14. Shields PG, Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18:2309-15.
15. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res 1992;52:6735-40.
16. Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin Oncol 1996;23:281-91.
17. Huang JQ, Sridhar S, Chen Y, et al: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
18. Guilford P, Hoplins J, Grady W, et al: E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402-5.
19. Dunbier A, Guilford P: Hereditary diffuse gastric cancer. Adv Cancer Res 2001;83:55-65.
20. Ebert MPD, Malfertheiner P: Pathogenesis of sporadic and familial gastric cancer-implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002;16:1059-66.
21. Lynch HT, de la Chapella A: Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-18.
22. Hemmiki K, Li X: Familial risk of cancer by site and histopathology. Int J Cancer 2003;103:105-9.
23. Espinoza LA, Barbieri NJ, Casartelli C: Pathological and karyotypic abnormalities in advanced gastric carcinomas: Cancer Genet Cytogenet 1999;109:45-50.
24. Kokkola A, Monni O, Puolakkainen P, et al: 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer 1997;20:38-43.
25. El-Rifai W, Hayper JC, Cummings OW, et al: Consistent genetic alterations in xenografts of proximal stomach and gastroesophagel junction adenocarcinoma. Cancer Res 1998; 58:34-7.
26. Sakakura C, Mori T, Sakabe T, et al: Gains, losses, and amplification of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Choromosomes Cancer 1999;24:299-305.
27. Guan XY, Fu SB, Xia JC, et al: Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000; 123: 27-34.
28. Wu MS, Chang MC, Huang SP, et al: Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer. Genes Chromosomes Cancer 2001;30:80-6.
29. Van Grieken NC, Weiss MM, Meijer GA, et al: Helicobacter pylori-related and non-related gastric cancers do not differ with respect to chromosomal aberrations. J Pathol 2000;192:301-6.
30. Noguchi T, Wirtz HC, Michaelis S, et al: Chromosomal imbalances in gastric cancer: Correlation with histologic subtypes and tumor progression. Am J Clin Pathol 2001; 115:802-34.
31. Wu CW, Chen GD, Fann CS, et al: Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. Genes Chromosomes Cancer 2002;35:219-31.
32. Van Dekken H, Alers JC, Riegman PH, et al: Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. AmJ Pathol 2001;158:1961-7.
33. zur Hausen A, van Grieken NC, Meijer GA, et al: Distinct chromosomal alterations in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization. Gastroenterology 2001;121:612-8.
34. Pinkel D, Segraves R, Sudar D, et al: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
35. El-Rifai W, Frierson HF Jr, Harper JC, et al: Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 2001; 92:832-8.
36. Hippo Y, Taniguchi H, Tsutsumi S, et al: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-40.
37. Mori M, Mimori K, Yoshikawa Y, et al: Analysis of gene-expression profile regarding the progression of humangastric carcinoma. Surgery 2002;131:39-47.
38. Ji J, Chen X, Leung SY, et al: Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene 2002;21:6549-56.
39. Lee S, Baek M, Yang H, et al: Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett 2002;184:197-206.
40. Sakakura C, Hagiwara A, Nakanishi M, et al: Differential gene expression profiles of gastric cancer cells established from primary tumor and malignant ascites. Br J Cancer 2002;87:1153-61.
41. Inoue H, Matsuyama A, Mimori K, et al: Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002;8:3475-9.
42. Leung SY, Chen X, Chu KM, et al. Phospholipase AZ group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 2002;99:16203-8.
43. Hasegawa S, Furukawa Y, Li M, et al: Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray repressenting 23,040 genes. Cancer Res 2002;62:7012-7.
44. Gulmann C, Butler D, Kay E, et al: Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 2003;42:70-6.
45. Yasui W, Yokozaki H, Fujimoto J, et al: Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000;35(Suppl XII):111-5.
46. Werner M, Becker KF, Keller G, et al: Gastric adenocarcinoma: Pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207-16.
47. Tamura G: Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 2002;17:323-9.
48. Park WS, Oh RR, Park JY, et al: Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59:4257-60.
49. Abraham SC, Nobukawa B, Giardiello FM, et al: Sporadic fundic gland polyps: common gastric polyps arising through activating mutation in the beta catenin gene. Am J Pathol 2001;158: 1005-10.
50. Ebert JH, Fei G, Kahmann S, et al. Increased beta-catenin mRNA levels and mutational alterations on the APC and beta-catenin gene are persent in intestinal type gastric cancer. Carcinogeness 2002;23:87-9.
51. Lee JH, Abraham SC, Kim HS, et al: Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol 2002;161:611-8.
52. Shiao YH, Rugge M, Correa P, et al: p53 alterations in gastric percancerous lesions. AmJ Pathol 1994;144:511-7.
53. Wu MS, Shun CT, Wang HP, et al: Genetic alterations of gastric cancer: relation to histological subtypes, tumor stage, and Helicobactor pylori infection. Gastroenterology 1997;112: 1457-65.
54. Yokozaki H, Shitara Y, Fujimoto J, et al: Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 1999;83:192-6.
55. Gunther T, Schneider-Stock R, Hackel C, et al: Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 2000; 13: 621-6.
56. Tannapfel A, Schmelzer S, Benicke M, et al: Expression of the p53 homologues p53 and p73 in multiple simultaneous gastric cancer. J Pathol 2001;195:163-70.
57. Wu MS, Lin YW, Sheu JC, et al: Intragenic homozygous deletions of MTS1 gene in gastric cancer in Taiwan. Jpn J Cancer Res 1996;87:1052-5.
58. Lee YY, Kang SH, Seo JY, et al: Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 1997;80: 1889-96.
59. Muller W, Noguchi T, Wirtz HC et al: Expression of all-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol 1999;189:186-93.
60. Takano Y, Kato Y, van Diest PJ, et al: Cyclin D2 overexpression and lack of p27 correlated positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156:585-94.
61. Liu XP, Kawauchi S, Oga A, et al: Combined examination of p27 (Kip 1) p21 (Waf1/cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 2001;39:603-10.
62. Suzuki T, Yasui W, Yokozaki H, et al: Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999;81: 535-8.
63. Takano Y, Kato Y, Masuda M, et al: Cyclin D2 but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 1999;189:194-200.
64. Ijichi H, Ikenoue T, Kato N, et al: Systematic analysis of the TGF-beta Smad signaling pathway in gastrointestinal cancer cells. Biochem Biophys Res Commun 2001;289:350-7.
65. Wu MS, Lee CW, Shun CT, et al: Clinicopathologic significance of altered loci of replication error and microsatellite instability associated mutations in gastric cancer. Cancer Res 1998;58: 1494-7.
66. Li QL, Ito K, Sakakura C, et al: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109: 113-24.
67. Lefebvre O, Chenard MP, Masson R, et al: Gastric mucosa abnormalities and tumorigenesis in mice lacking the PS2 trefoil protein. Science 1996;274:259-62.
68. Carvalho R, Kayademir T, Soares P, et al: Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF 1 in gastric carcinoma. Lab Invest 2002;82:1319-26.
69. Wu MS, Shun CT, Wang HP, et al: Loss of pS2 expression is an early event in intestinal type gastric cancer. Jpn J Cancer Res 1998;89:278-82.
70. Taupin D, Pedersen J, Familari M, et al: Augmented intestinal trefoil factor (TFF3) and loss of ps2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium, Lab Invest 2001; 81:397-408.
71. Leung WK, Yu J, Chan FK, et al: Expression of trefoil peptides (TFF1, TFF2, TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 2002;197:582-8.
72. Tebbutt NC, Giraud AS, Inglese M, et al: Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAF mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002;8: 1089-97
73. Azarschab P, Al-Azzeh E, Kornberger W, et al: Aspirin promotes TFF2 gene activation in human gastric cancer cell lines. FEBS Lett 2001;488:206-10.
74. Wu CW, Li AF, Chi CW, et al: Human gastric cancer kinase profile and prognostic significance of MKK4 kinase. Am J Pathol 2000;156:2007-15.
75. Arber N, Shapira I, Ratan J, et al: Activation of C-K-ras mutations in human gastrointestinal tumors. Gastroenterology 2000;118: 1045-50.
76. Chen CN, Sung CT, Lin MT, et al: Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 in gastric cancer. Ann Surg 2001;233:183-8.
77. Lin JT, Wu MS, Shun CT, et al: Microsatellite instability in gastric carcinoma with special reference to histopathology and cancer stages. Eur J Cancer 1995;31:1879-82.
78. Lin JT, Wu MS, Shun CT, et al: Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein. Cancer Res 1995;55:1428-30.
79. Wu MS, Lee CW, Shun CT, et al: Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 2000;27:403-11.
80. Kang GH, Shin YH, Jung HY, et al: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-51.
81. Waki T, Tamura G, Tsuchiya T, et al: Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J pathol 2002;161:399-403.
82. Que N, Motoshita J, Yokozaki H, et al: Distinct promoter hypermethylation of p16 INK4a, CHD1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 2002;198:55-9.
83. Shibata DM, Sato F, Mori Y, et al: Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res 2002;62:5637-40.
84. To KF, Leung WK, Lee TL, et al: Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002;102:623-8.
85. Wu MS, Shun CT, Wu CC, et al: Epstein-Barr-virus-associated gastric carcinomas: relation to helicobacter pylori infection and genetic alterations. Gastoenterology 2000;118;1031-8.
86. Chang YT, Wu MS, Chang CJ, et al: Preferential loss of Fhit expression in signet-ring cell and Krukenberg subtype of gastric cancer. Lab Invest 2002;82:1201-8.
87. Wu MS, Huang SP, Chang YT, et al: Tumor necrosis factor-α and interleukin-10 promoter polymorphisms in Epstein-Barr virus associated gastric carcinoma. J Infect Dis 2002;185:106-9.
88. Wu MS, Huang SP, Chang YT, et al: Association of the -160C → A promoter polymorphism of E-cadherin gene with gastric cancer risk. Cancer 2002;94:1443-8.
89. Wu MS, Hsieh RP, Huang SP, et al: Association of HLA-DQB1(*) 0301 and HLA-DQB1(*)0602 with different subtypes of gastric cancer in Taiwan. Jpn J Cancer Res 2002;93:404-10.
90. Wu MS, Chen CJ, Lin MT, et al: Genetic polymorphisms of cytochrome p450 2E1, glutathione S-transferase M1 and T1, and susceptibility to gastric carcinoma in Taiwan. In J Colorectal Dis 2002;17:338-43.
91. Gonzales CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk, Int J Cancer 2002;100:249-60.
92. Kato S, Onda M, Yamada S, et al: Association of interleukin-1 beta genetic polymorphisms and gastric cancer risk in Japanese. J Gastroenterol 2001;36:696-9.
93. Wu MS, Wu CY, Chen CJ, et al: Interleukin-10 genotypes associated with risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 2003;104:617-23.
94. Figueiredo C, Machado C, Pharoah P, et al: Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for carcinoma. J Natl Cancer Inst 2002;94:1680-7.
95. Thye T, Burchard GD, Nilius M, et al: Genomewide linkage analysis identifies polymorphism in the human interferon-γ receptor affecting Helicobacter pylori infection. Am J Hum Genet 2003;72:448-53.